{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:07:08Z","timestamp":1790935628712,"version":"4.1.0"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"13","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immunotherapy with rituximab alone or in conjunction with chemotherapy has significantly improved the treatment outcome of B-cell lymphoma patients. Nevertheless, a subpopulation of patients does not respond to rituximab. The reason for treatment failure as well as the exact mechanism of action is still uncertain. The function of rituximab has long been associated with the partitioning of CD20 molecules to lipid microdomains. We now show that the extent of CD20 recruitment to lipid rafts correlates with response to rituximab. In addition, expression of the raft-associated sphingolipid GM1 on lymphoma cells is associated with the susceptibility of lymphoma cells to rituximab. Furthermore, we show substantially different GM1 expression in various primary non-Hodgkin's lymphomas. Whereas chronic lymphocytic leukemia (CLL) cells have a low GM1 expression, marginal zone lymphoma cells exhibit much higher levels. Differences were not only detected among various lymphoma subgroups but also within one lymphoma subtype. Interestingly, whereas CLL cells from patients with high GM1 expression responded to rituximab, patients with low GM1 expressing CLL cells did not. These data show the importance of membrane microdomains in the effect of rituximab and may offer a predictive factor for the responsiveness of lymphoma cells to rituximab. [Cancer Res 2008;68(13):5414\u201322]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-5601","type":"journal-article","created":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T17:53:53Z","timestamp":1214934833000},"page":"5414-5422","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["GM1 Expression of Non-Hodgkin's Lymphoma Determines Susceptibility to Rituximab Treatment"],"prefix":"10.1158","volume":"68","author":[{"given":"Christian","family":"Meyer zum Bu\u0308schenfelde","sequence":"first","affiliation":[{"name":"III Medical Department, Klinikum rechts der Isar, Technical University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Feuerstacke","sequence":"additional","affiliation":[{"name":"III Medical Department, Klinikum rechts der Isar, Technical University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina S.","family":"Go\u0308tze","sequence":"additional","affiliation":[{"name":"III Medical Department, Klinikum rechts der Isar, Technical University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Scholze","sequence":"additional","affiliation":[{"name":"III Medical Department, Klinikum rechts der Isar, Technical University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Peschel","sequence":"additional","affiliation":[{"name":"III Medical Department, Klinikum rechts der Isar, Technical University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,7,1]]},"reference":[{"key":"2022061700402523800_B1","unstructured":"Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood\u20081998; 92: 1927\u201332."},{"key":"2022061700402523800_B2","unstructured":"Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol\u20081999; 26: 88\u201396."},{"key":"2022061700402523800_B3","doi-asserted-by":"crossref","unstructured":"Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med\u20081993; 329: 459\u201365.","DOI":"10.1056\/NEJM199308123290703"},{"key":"2022061700402523800_B4","doi-asserted-by":"crossref","unstructured":"Press OW, Leonard JP, Coiffier B, Levy R, Timmerman J. Immunotherapy of non-Hodgkin's lymphomas. Hematol Am Soc Hematol Educ Program 2001:221\u201340.","DOI":"10.1182\/asheducation-2001.1.221"},{"key":"2022061700402523800_B5","doi-asserted-by":"crossref","unstructured":"Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene\u20082003; 22: 7359\u201368.","DOI":"10.1038\/sj.onc.1206939"},{"key":"2022061700402523800_B6","doi-asserted-by":"crossref","unstructured":"Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med\u20082000; 6: 443\u20136.","DOI":"10.1038\/74704"},{"key":"2022061700402523800_B7","doi-asserted-by":"crossref","unstructured":"Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood\u20082003; 101: 1045\u201352.","DOI":"10.1182\/blood-2002-06-1761"},{"key":"2022061700402523800_B8","doi-asserted-by":"crossref","unstructured":"Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood\u20082001; 98: 3383\u20139.","DOI":"10.1182\/blood.V98.12.3383"},{"key":"2022061700402523800_B9","doi-asserted-by":"crossref","unstructured":"Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm\u20081997; 12: 177\u201386.","DOI":"10.1089\/cbr.1997.12.177"},{"key":"2022061700402523800_B10","doi-asserted-by":"crossref","unstructured":"Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood\u20081998; 91: 1644\u201352.","DOI":"10.1182\/blood.V91.5.1644"},{"key":"2022061700402523800_B11","doi-asserted-by":"crossref","unstructured":"Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol\u20082003; 171: 1581\u20137.","DOI":"10.4049\/jimmunol.171.3.1581"},{"key":"2022061700402523800_B12","doi-asserted-by":"crossref","unstructured":"Weng WK, Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood\u20082001; 98: 1352\u20137.","DOI":"10.1182\/blood.V98.5.1352"},{"key":"2022061700402523800_B13","doi-asserted-by":"crossref","unstructured":"Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood\u20082004; 104: 2635\u201342.","DOI":"10.1182\/blood-2004-03-1110"},{"key":"2022061700402523800_B14","doi-asserted-by":"crossref","unstructured":"Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res\u20082004; 64: 4664\u20139.","DOI":"10.1158\/0008-5472.CAN-03-2862"},{"key":"2022061700402523800_B15","doi-asserted-by":"crossref","unstructured":"Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc\u03b3RIIIa gene. Blood\u20082002; 99: 754\u20138.","DOI":"10.1182\/blood.V99.3.754"},{"key":"2022061700402523800_B16","doi-asserted-by":"crossref","unstructured":"Perz J, Topaly J, Fruehauf S, Hensel M, Ho AD. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leuk Lymphoma\u20082002; 43: 149\u201351.","DOI":"10.1080\/10428190210178"},{"key":"2022061700402523800_B17","doi-asserted-by":"crossref","unstructured":"Simons K, Ikonen E. Functional rafts in cell membranes. Nature\u20081997; 387: 569\u201372.","DOI":"10.1038\/42408"},{"key":"2022061700402523800_B18","doi-asserted-by":"crossref","unstructured":"Fukumoto S, Mutoh T, Hasegawa T, et al. GD3 synthase gene expression in PC12 cells results in the continuous activation of TrkA and ERK1\/2 and enhanced proliferation. J Biol Chem\u20082000; 275: 5832\u20138.","DOI":"10.1074\/jbc.275.8.5832"},{"key":"2022061700402523800_B19","doi-asserted-by":"crossref","unstructured":"Miljan EA, Bremer EG. Regulation of growth factor receptors by gangliosides. Sci STKE\u20082002; 2002: RE15.","DOI":"10.1126\/scisignal.1602002re15"},{"key":"2022061700402523800_B20","doi-asserted-by":"crossref","unstructured":"Mitsuda T, Furukawa K, Fukumoto S, Miyazaki H, Urano T, Furukawa K. Overexpression of ganglioside GM1 results in the dispersion of platelet-derived growth factor receptor from glycolipid-enriched microdomains and in the suppression of cell growth signals. J Biol Chem\u20082002; 277: 11239\u201346.","DOI":"10.1074\/jbc.M107756200"},{"key":"2022061700402523800_B21","doi-asserted-by":"crossref","unstructured":"Mutoh T, Tokuda A, Miyadai T, Hamaguchi M, Fujiki N. Ganglioside GM1 binds to the Trk protein and regulates receptor function. Proc Natl Acad Sci U S A\u20081995; 92: 5087\u201391.","DOI":"10.1073\/pnas.92.11.5087"},{"key":"2022061700402523800_B22","doi-asserted-by":"crossref","unstructured":"Yamashita T, Hashiramoto A, Haluzik M, et al. Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc Natl Acad Sci U S A\u20082003; 100: 3445\u20139.","DOI":"10.1073\/pnas.0635898100"},{"key":"2022061700402523800_B23","unstructured":"Inokuchi JI, Uemura S, Kabayama K, Igarashi Y. Glycosphingolipid deficiency affects functional microdomain formation in Lewis lung carcinoma cells. Glycoconj J\u20082000; 17: 239\u201345."},{"key":"2022061700402523800_B24","doi-asserted-by":"crossref","unstructured":"Nagafuku M, Kabayama K, Oka D, et al. Reduction of glycosphingolipid levels in lipid rafts affects the expression state and function of glycosylphosphatidylinositol-anchored proteins but does not impair signal transduction via the T cell receptor. J Biol Chem\u20082003; 278: 51920\u20137.","DOI":"10.1074\/jbc.M307674200"},{"key":"2022061700402523800_B25","doi-asserted-by":"crossref","unstructured":"Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol\u20082000; 1: 31\u20139.","DOI":"10.1038\/35036052"},{"key":"2022061700402523800_B26","doi-asserted-by":"crossref","unstructured":"Zambello R, Cabrelle A, Trentin L, Agostini C, Semenzato G, Viola A. The raft marker GM1 identifies functional subsets of granular lymphocytes in patients with CD3+ lymphoproliferative disease of granular lymphocytes. Leukemia\u20082004; 18: 771\u20136.","DOI":"10.1038\/sj.leu.2403292"},{"key":"2022061700402523800_B27","doi-asserted-by":"crossref","unstructured":"Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood\u20082000; 95: 999\u20131006.","DOI":"10.1182\/blood.V95.3.999.003k10_999_1006"},{"key":"2022061700402523800_B28","doi-asserted-by":"crossref","unstructured":"Inokuchi J, Radin NS. Preparation of the active isomer of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, inhibitor of murine glucocerebroside synthetase. J Lipid Res\u20081987; 28: 565\u201371.","DOI":"10.1016\/S0022-2275(20)38673-9"},{"key":"2022061700402523800_B29","doi-asserted-by":"crossref","unstructured":"Ferch U, Meyer zum Buschenfelde C, Gewies A, et al. MALT1 directs B cell receptor-induced canonical nuclear factor-\u03baB signaling selectively to the c-Rel subunit. Nat Immunol\u20082007; 8: 984\u201391.","DOI":"10.1038\/ni1493"},{"key":"2022061700402523800_B30","doi-asserted-by":"crossref","unstructured":"Cheng PC, Dykstra ML, Mitchell RN, Pierce SK. A role for lipid rafts in B cell antigen receptor signaling and antigen targeting. J Exp Med\u20081999; 190: 1549\u201360.","DOI":"10.1084\/jem.190.11.1549"},{"key":"2022061700402523800_B31","doi-asserted-by":"crossref","unstructured":"Yanagisawa M, Nakamura K, Taga T. Glycosphingolipid synthesis inhibitor represses cytokine-induced activation of the Ras-MAPK pathway in embryonic neural precursor cells. J Biochem (Tokyo)\u20082005; 138: 285\u201391.","DOI":"10.1093\/jb\/mvi129"},{"key":"2022061700402523800_B32","unstructured":"Chan HT, Hughes D, French RR, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res\u20082003; 63: 5480\u20139."},{"key":"2022061700402523800_B33","doi-asserted-by":"crossref","unstructured":"Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood\u20082004; 103: 2738\u201343.","DOI":"10.1182\/blood-2003-06-2031"},{"key":"2022061700402523800_B34","doi-asserted-by":"crossref","unstructured":"Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med\u20082004; 199: 1659\u201369.","DOI":"10.1084\/jem.20040119"},{"key":"2022061700402523800_B35","doi-asserted-by":"crossref","unstructured":"Bezombes C, Grazide S, Garret C, et al. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood\u20082004; 104: 1166\u201373.","DOI":"10.1182\/blood-2004-01-0277"},{"key":"2022061700402523800_B36","doi-asserted-by":"crossref","unstructured":"Tepper AD, de Vries E, van Blitterswijk WJ, Borst J. Ordering of ceramide formation, caspase activation, and mitochondrial changes during CD95- and DNA damage-induced apoptosis. J Clin Invest\u20081999; 103: 971\u20138.","DOI":"10.1172\/JCI5457"},{"key":"2022061700402523800_B37","doi-asserted-by":"crossref","unstructured":"Li H, Ayer LM, Polyak MJ, et al. The CD20 calcium channel is localized to microvilli and constitutively associated with membrane rafts: antibody binding increases the affinity of the association through an epitope-dependent cross-linking-independent mechanism. J Biol Chem\u20082004; 279: 19893\u2013901.","DOI":"10.1074\/jbc.M400525200"},{"key":"2022061700402523800_B38","doi-asserted-by":"crossref","unstructured":"Deans JP, Kalt L, Ledbetter JA, Schieven GL, Bolen JB, Johnson P. Association of 75\/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J Biol Chem\u20081995; 270: 22632\u20138.","DOI":"10.1074\/jbc.270.38.22632"},{"key":"2022061700402523800_B39","doi-asserted-by":"crossref","unstructured":"Hamaguchi Y, Uchida J, Cain DW, et al. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol\u20082005; 174: 4389\u201399.","DOI":"10.4049\/jimmunol.174.7.4389"},{"key":"2022061700402523800_B40","unstructured":"Bennett M, Sharma K, Yegena S, Gavish I, Dave HP, Schechter GP. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica\u20082005; 90: 856\u20138."},{"key":"2022061700402523800_B41","doi-asserted-by":"crossref","unstructured":"Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood\u20082001; 98: 1326\u201331.","DOI":"10.1182\/blood.V98.5.1326"},{"key":"2022061700402523800_B42","doi-asserted-by":"crossref","unstructured":"O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol\u20082001; 19: 2165\u201370.","DOI":"10.1200\/JCO.2001.19.8.2165"},{"key":"2022061700402523800_B43","doi-asserted-by":"crossref","unstructured":"Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol\u20082005; 23: 4079\u201388.","DOI":"10.1200\/JCO.2005.12.051"},{"key":"2022061700402523800_B44","doi-asserted-by":"crossref","unstructured":"Farag SS, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC. Fc\u03b3RIIIa and Fc\u03b3RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood\u20082004; 103: 1472\u20134.","DOI":"10.1182\/blood-2003-07-2548"},{"key":"2022061700402523800_B45","doi-asserted-by":"crossref","unstructured":"Ghielmini M, Rufibach K, Salles G, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol\u20082005; 16: 1675\u201382.","DOI":"10.1093\/annonc\/mdi320"},{"key":"2022061700402523800_B46","doi-asserted-by":"crossref","unstructured":"Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood\u20082006; 108: 4003\u20138.","DOI":"10.1182\/blood-2006-04-016725"},{"key":"2022061700402523800_B47","doi-asserted-by":"crossref","unstructured":"Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule. Blood\u20082004; 103: 4416\u201323.","DOI":"10.1182\/blood-2003-10-3411"},{"key":"2022061700402523800_B48","doi-asserted-by":"crossref","unstructured":"Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol\u20082003; 21: 1746\u201351.","DOI":"10.1200\/JCO.2003.09.027"},{"key":"2022061700402523800_B49","doi-asserted-by":"crossref","unstructured":"Hainsworth JD, Litchy S, Burris HA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol\u20082002; 20: 4261\u20137.","DOI":"10.1200\/JCO.2002.08.674"},{"key":"2022061700402523800_B50","doi-asserted-by":"crossref","unstructured":"Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol\u20082005; 23: 1088\u201395.","DOI":"10.1200\/JCO.2005.12.191"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/13\/5414\/2595247\/5414.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/13\/5414\/2595247\/5414.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T06:00:28Z","timestamp":1655445628000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/13\/5414\/541021\/GM1-Expression-of-Non-Hodgkin-s-Lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,1]]},"references-count":50,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2008,7,1]]},"published-print":{"date-parts":[[2008,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-5601","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,1]]}}}